Assays for the detection of anti-TNF drugs and autoantibodies
View Patent ↗The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
1. A method for determining the presence or level of an autoantibody to a therapeutic antibody for treating an autoimmune disease in a sample, the method comprising:
(a) contacting a labeled therapeutic antibody with the sample to form a labeled complex with the autoantibody;
(b) subjecting the labeled complex to size exclusion chromatography to separate the labeled complex from free labeled therapeutic antibody and to detect an amount of the labeled complex and an amount of the free labeled therapeutic antibody; and
(c) comparing a ratio of the amount of the labeled complex and the amount of the free labeled therapeutic antibody detected in step (b) to a standard curve of known amounts of the autoantibody, thereby determining the presence or level of the autoantibody.
2. The method of claim 1 , wherein the standard curve is generated by incubating the labeled therapeutic antibody with serum positive for the autoantibody.
3. The method of claim 1 , wherein the sample is serum.
4. The method of claim 1 , wherein the autoimmune disease is a member selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, B-cell non-Hodgkin's lymphoma, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, severe psoriasis, chronic uveitis, severe sarcoidosis, and Wegener's granulomatosis.
5. The method of claim 1 , wherein the therapeutic antibody is a member selected from the group consisting of an anti-cytokine antibody, an anti-chemokine antibody, an anti-cell adhesion antibody, an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD20 antibody, and an anti-CD25 antibody.
6. The method of claim 5 , wherein the anti-cytokine antibody is a member selected from the group consisting of Actemra (tocilizumab) and CNTO 1275 (ustekinumab).
7. The method of claim 5 , wherein the anti-cell adhesion antibody is natalizumab.
8. The method of claim 5 , wherein the anti-CD3 antibody is visilizumab.
9. The method of claim 5 , wherein the anti-CD4 antibody is priliximab.
10. The method of claim 5 , wherein the anti-CD20 antibody is a member selected from the group consisting of rituximab, ofatumumab, and ocrelizumab.
11. The method of claim 5 , wherein the anti-CD25 antibody is daclizumab.
12. The method of claim 1 , wherein the autoantibody is a member selected from the group consisting of a human anti-mouse antibody (HAMA), a human anti-chimeric antibody (HACA), a human anti-humanized antibody (HAHA), and combinations thereof.
13. The method of claim 1 , wherein the size exclusion chromatography is size exclusion-high performance liquid chromatography (SE-HPLC).
14. The method of claim 1 , wherein the labeled therapeutic antibody is a fluorophore-labeled therapeutic antibody.
15. The method of claim 14 , wherein the fluorophore is an Alexa Fluor® dye.
16. The method of claim 1 , wherein the labeled complex is eluted first, followed by the free labeled therapeutic antibody.
17. The method of claim 1 , wherein the sample is obtained from a subject receiving therapy with the therapeutic antibody.
18. The method of claim 1 , wherein a ratio of the free labeled therapeutic antibody to an internal control is determined and used to extrapolate the level of the autoantibody from the standard curve.